(Photo Courtesy: www.rethinkcanada.com)
"Overall, we expect the R&D-to-sales ratio to increase in the coming years," said Bayer's management board chairman Dr Marijn Dekkers at Bayer's Perspective on Innovation 2014 press forum in Leverkusen, Germany.
The research and development budget in the life science businesses this year amounts to €3.2 billion.
Of this amount, Bayer healthcare accounts for 70 percent and Bayer cropscience for 30 percent.
Dr Dekkers said that as a world-class lifescience company, Bayer will continue to target attractive markets with high growth rates, and in following this course, it has very good prospects for the future.
He explained that the company has more than 13,000 employees in research and development, 61 percent of them in healthcare and 39 percent in cropscience, and that it has made major progress in both businesses.